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The accumulation and aggregation of alpha-synuclein (α-syn) in several tissue including the brain is a major
pathological hallmark in Parkinson’s disease (PD). In this study, we show that α-syn can be taken up by primary
human cortical neurons, astrocytes and skin-derived fibroblasts in vitro. Our findings that brain and peripheral cells
exposed to α-syn can lead to impaired mitochondrial function, leading to cellular degeneration and cell death,
provides additional evidence for the involvement of mitochondrial dysfunction as a mechanism of toxicity of α-syn
in human cells.
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Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder after Alzheimer’s disease (AD) [1].
This debilitating degenerative movement disorder is char-
acterized symptomatically by resting tremor, bradykinesia,
muscle tone rigidity and impaired autonomic, sensory and
cognitive function. These motor deficits are attributed to
the selective loss of dopaminergic neurons projecting from
the substantia nigra to the midbrain. Dystrophic neurons
typically contain cytosolic protein aggregates (“Lewy bod-
ies”) composed largely of the presynaptic protein alpha-
synuclein [1]. While numerous neurotoxins and genes
have been implicated in the development of PD, the exact
aetiology of PD remains unclear [1-5]. Accumulative evi-
dence suggests that α-syn may be involved in the initiation
and disease progression [6,7]. Familial forms of PD are as-
sociated with either missense of gene mutations in the
SNCA gene encoding for α-syn [8]. Mutations in the α-
syn gene locus represents an important risk factor for PD
in several genome-wide association studies using large co-
horts worldwide [9].* Correspondence: Daniel.Chan@sswahs.nsw.gov.au
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reproduction in any medium, provided the orThe α-syn is a cytosolic protein that can be released
from neuronal cells in small amounts via unconven-
tional exocytosis under normal physiological conditions
[10,11]. However, in the presence of several stressors, α-
syn may be released from neuronal cells into the sur-
rounding extracellular space in larger quantities and
taken up by neighbouring cells by endocytosis [10,11].
However, little is known regarding the effect of human
recombinant α-syn on other cells of the brain and sur-
rounding tissue.
In this study, we have shown that human recombinant
α-syn can be taken up by human primary astrocytes,
cortical neurons and fibroblasts. We also show that this
may lead to increased intracellular oxygen consumption
and cell death after 24 hour exposure. The effect of α-
syn in vitro, even in cultured fibroblasts, suggests that
PD may be a systemic illness, with primary pathological
changes occurring in the brain.Materials and methods
Reagents and chemicals
Dulbecco’s phosphate buffer solution (DPBS) and all other
cell culture media and supplements were from Invitrogen
(Melbourne, Australia) unless otherwise stated. Mouse
mAb anti-α-syn, DAPI, and pAb anti-GFAP were obtained
from Sigma-Aldrich (Castle-Hill, Australia). Rabbit anti-td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(Melbourne, Australia). Secondary anti-mouse IgG and
anti-rabbit Alexa 488 (green) or Alexa 594 (red)-conju-
gated antibodies were purchased from Molecular Probes
(Eugene, OR). All commercial antibodies were used at the
concentrations specified by the manufacturers.
Cell cultures
Human foetal brains, and skin were obtained from
16–19 week old foetuses collected following therapeutic
termination with informed consent. Mixed brain cul-
tures were prepared and maintained using a protocol
previously described [12].
Astrocytes were prepared from the mixed brain cell cul-
tures using a protocol previously described [13]. Cells were
cultured in medium RPMI 1640 (Invitrogen) supplemented
with 10% foetal bovine serum, 1% 1-glutamax, 1% antibac-
terial/antifungal, and 0.5% glucose. Cells were seeded into
24-well tissue culture plates to a density of 1 × 105 cells
24 hours prior to experimentation.
Human foetal cortical neurons were prepared from
mixed brain cell cultures as previously described [14].
Briefly, cortical neurons were plated in 24-well culture
plates coated with Matrigel (BD Biosciences) diluted
1/20 in Neurobasal (Invitrogen). The culture medium was
changed every second day and consisted of Neurobasal
medium supplemented with 1% B-27 supplement, 1%
Glutamax, 1% antibiotic/antifungal, and 0.5% glucose.
Fibroblasts were prepared from the skin using a proto-
col as previously described [15]. All cell cultures were
maintained in an incubator at 37°C in a humidified at-
mosphere containing 95% air/5% CO2.
Uptake of recombinant extracellular α-synuclein
Recombinant α-synuclein was expressed in Escherichia coli
BL21(DE3) transformed with the pET11d vector containing
the human α-synuclein cDNA described previously [16].
For uptake of recombinant α-syn in primary astrocytes,
cortical neurons and skin-derived fibroblasts, human α-syn
was incubated overnight at 37°C to form oligomers and
then labelled with Alexa Fluor 488 (Invitrogen) as per the
manufacturer’s instructions. Cells were incubated with ex-
pansion media containing 1 μM Alexa-Fluor-488-labelled
α-syn for 30 min and 60 min. Cells were washed twice with
PBS to ensure that the uptake of exogenous α-syn was not
due to non-specific binding of α-syn to the cells.Cells were
fixed with 4% paraformaldehyde diluted in DPBS.
Immunocytochemistry for the detection of α-syn uptake
The method for immunocytochemistry has been previ-
ously described [17]. Cells were incubated with selected
primary antibody mAb α-syn, together with phenotypic
markers (GFAP, MAP-2, Fibronectin) and antibody
against the inner mitochondrial membrane protein,complex V (ATPase) (Abcam). Selected secondary anti-
bodies (goat anti-mouse IgG or goat anti-rabbit coupled
with Alexa 488 or Alexa 594) were used. The following
controls were performed for each labelled experiment:
(1) isotypic antibody controls; and (2) incubation with
only the secondary labelled antibody.
Extracellular LDH activity as a measurement for
cytotoxicity
The release of lactate dehydrogenase (LDH) into culture
supernatant correlates with the amount of cell death and
membrane damage, providing an accurate measure of cel-
lular toxicity. LDH activity was assayed on cortical neurons,
astrocytes and skin-derived fibroblasts treated with 5 μM
recombinant α-syn after 24 hours incubation using a stand-
ard spectrophotometric technique described by [18].
XF24 Microplate-based respirometry
To determine the effect of exogenous recombinant α-syn
(5 μM) on oxygen consumption rates (OCRs; as indicator
of mitochondrial respiration) in cortical neurons, primary
astrocytes, and skin-derived fibroblasts, the Seahorse
XF24, extracellular flux analyzer (Seahorse Bioscience,
North Billerica, MA, USA) was employed as previously
described. Briefly, culture plates were incubated in a CO2-
free incubator at 37°C for 1 hr to equilibrate for tempe-
rature and pH. The microplate was then loaded into the
XF24 and further incubated for 15 min by 3 min mix,
2 min wait cycles before commencement of the assay. The
XF assay was performed as previous described [19]. After
determination of the basal respiration in the cell culture,
oligomycin (2 μM), carbonylcyanide-p-trifluoromethoxy-
phenylhydrazone (FCCP, 500 nM), and antimycin (3 μM)
were sequentially added and the oxygen consumption
rates (OCRs) for each culture well were quantified for
2 minutes. This allowed us to determine the basal control
ratio (BCR) and the uncoupling ratio (UCR) [20]. Essen-
tially, the BCR is a measurement of how close the basal
level of respiration is to the maximum level of respiration
(i.e., basal/maximum). The closer this ratio is to 1, the
lower the maximum level of respiration, and thus repre-
sents an indication of mitochondrial malfunction. The
UCR is a measurement of mitochondrial functional integ-
rity and measures the ratio of uncoupled to physiologically
normal respiration levels (i.e., maximum/basal). The grea-
ter the maximum level of respiration, the greater the mito-
chondrial functional integrity.
Bradford protein assay for the quantification of total protein
Extracellular LDH activity, NAD+ concentration, nuclei
and mitochondrial protein content, and mitochondrial
function were corrected for variations in protein con-
centration using the Bradford protein assay described
by Bradford [21].
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Results obtained are presented as the means ± the
standard error of measurement (SEM). One way
analysis of variance (ANOVA) and post hoc Tukey’s
multiple comparison tests were used to determine stat-
istical significance between treatment groups. Differ-
ences between treatment groups were considered
significant if p was less than 0.05 (p < 0.05). Experi-
ments were performed in triplicates using cells derived
from three different specimens unless otherwise stated.
Results
Time dependent uptake of α-syn in cultured human
cortical neurons, astrocytes and skin-derived fibroblasts
To reaffirm the uptake of extracellular α-syn aggregates
in human astrocytes, cortical neurons and fibroblasts,Figure 1 α-syn uptake in human primary cortical neurons cells. (i) Co
human cortical neurons. Staining for Alexa-Fluor-488-labelled α-syn in hum
double staining for α-syn/green and DAPI/blue; Bottom, Merged MAP-2/red
semi-quantification of the immunostaining intensity. Intensity has been qu
triplicate with primary cultures of cortical neurons prepared from three diff
for each treatment and the SEM for the data was determined to be 5%. * iprimary cultures were incubated with cell culture media
containing Alexa-Fluor-488 labelled α-syn. Immuno-
fluorescence analysis displayed in this study have
highlighted the potential ability of these cell to uptake α-
syn in a time-dependent manner (Figures 1, 2 and 3).
Cytotoxic effects of α-syn in enteric neurons is associated
increased intracellular oxygen consumption leading to
cell death
A recently study showed that recombinant extracellular
α-syn forms cytoplasmic bodies capable of inducing tox-
icity at 5 μM after 24 hours incubation in SH-SY5Y
neuroblastoma cell line [22]. Using the same dose and
exposure time, we investigated the cytotoxic effect of re-
combinant α-syn in human astrocytes, cortical neurons
and fibroblasts. A significant increase in basal controlnfocal microscopy analysis of α-syn uptake after 30 and 60 min in
an neurons: Top, double staining for MAP-2/red and DAPI/blue; Centre,
, α-syn/green and DAPI/blue. (ii) The histogram represents the
antified using ImageJ 10.2. This experiment has been performed in
erent brain samples. Three individual microscopic fields were analysed
ndicate the level of significance (p < 0.05).
Figure 2 α-syn uptake in human primary astrocytes. (i) Confocal microscopy analysis of α-syn uptake after 30 and 60 min in human
astrocytes. Staining for Alexa-Fluor-488-labelled α-syn in human neurons: Top, double staining for GFAP/red and DAPI/blue; Centre, double
staining for α-syn/green and DAPI/blue; Bottom, Merged GFAP/red, α-syn/green and DAPI/blue. (ii) The histogram represents the
semi-quantification of the immunostaining intensity. Intensity has been quantified using ImageJ 10.2. This experiment has been performed in
triplicate with primary cultures of astrocytes prepared from three different brain samples. Three individual microscopic fields were analysed for
each treatment and the SEM for the data was determined to be 5%. * indicate the level of significance (p < 0.05).
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observed after 24 hours incubation when these cells were
treated with medium containing recombinant α-syn using
the Seahorse XF24 (Seahorse Bioscience) (Figure 4). We
further confirmed that α-syn is cytotoxic to the mitochon-
dria by demonstrating that exogenous α-syn is localised in
the mitochondria of the host cell (Figure 5). Increased
extracellular LDH activity was also observed in these cells
after 24 hours (Figure 6).
Discussion
The current study uses several cell culture models: 1) to re-
affirm whether recombinant α-syn can be taken up by pri-
mary human astrocytes, cortical neurons and fibroblasts;
2) to determine the effect of α-syn on mitochondrial func-
tion in brain and periphery cells using Seahorse XF240. A
key finding of the current investigation is that α-syn canaccumulate in several cell types in vitro not restricted to
the brain, in a time dependent manner leading to increased
intracellular oxygen consumption and cell death.
Owing to the diverse clinical symptoms associated with
PD, it is likely that multiple brain systems may be im-
paired. Indeed, Lewy bodies are widely distributed in the
several areas of the brain, including the midbrain, cere-
brum and brainstem corresponding to axonal projections
[23]. Earlier studies have suggested that misfolded α-syn
may propagate from neuron to neuron in a prion-like
manner, causing endogenous α-syn to misfold [11]. Re-
cently, Freundt et al. [24] showed that fibrillar α-synuclein
can be internalized by primary mouse neurons via rapid
axonal transport with saltatory movement [24]. Moreover,
Angot et al. [25] showed that α-syn can be transferred
between neuronal host cells and grafted dopaminergic
neurons in vivo [25]. However, our data is the first to
Figure 4 Effects of α-syn on mitochondrial function in human primary cortical neurons, astrocytes and skin-derived fibroblasts. The
BCR and UCR were determined in (i) human primary cortical neurons, (ii) astrocytes and (iii) skin-derived fibroblasts pre-treated with 5 μM
recombinant α-syn for 24 hours. Significance *p < 0.05 compared to non-treated cells. (n = 4 for each treatment group).
Figure 3 α-syn uptake in human primary skin derived fibroblasts. (i) Confocal microscopy analysis of α-syn uptake after 30 and 60 min in
human skin-derived fibroblasts. Staining for Alexa-Fluor-488-labelled α-syn in human neurons: Top, double staining for Fibronectin/red and DAPI/
blue; Centre, double staining for α-syn/green and DAPI/blue; Bottom, Merged Fibronectin /red, α-syn/green and DAPI/blue. (ii) The histogram
represents the semi-quantification of the immunostaining intensity. Intensity has been quantified using ImageJ 10.2. This experiment has been
performed in triplicate with primary cultures of fibroblasts prepared from three different fetal skin samples. Three individual microscopic fields
were analysed for each treatment and the SEM for the data was determined to be 5%. * indicate the level of significance (p < 0.05).
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Figure 5 Localisation of recombinant α-syn to the mitochondria in human primary (A) cortical neurons (B) astrocytes, and (C) skin
derived fibroblasts. Confocal microscopy analysis of α-syn uptake after 24 hours. Dual immunocytochemical staining for α-syn using the
anti-alpha-syn antibody (R & D systems, Minneapolis, MN) (green) and inner mitochondrial membrane protein, complex V (ATPase, red).
Braidy et al. Translational Neurodegeneration 2013, 2:20 Page 6 of 9
http://www.translationalneurodegeneration.com/content/2/1/20demonstrate the uptake of exogenous α-syn oligomers in
human primary cortical neurons. Taken together, these re-
sults support the hypothesis that PD can be caused by
neuron-to-neuron spread of α-syn aggregates involving
axonal transport of fibrillar and/or oligomers.
Glial inclusions, which are common pathological fea-
tures in PD, have been shown to occur as a result of
neuron-to-glia transmission of α-syn protein [26]. Here,
we show that human primary astrocytes can also uptake
α-syn oligomers similar to murine glial cells. One study
showed that glial accumulation of α-syn proteins released
from murine neuronal cells may involve endocytosis lead-
ing to the formation of cytoplasmic inclusion bodies [27].
Furthermore, astrocytes exposed to neuronal α-syn exhi-
bited significant changes in their gene expression profile
providing biochemical evidence for an inflammatory re-
sponse. Up-regulation of pro-inflammatory cytokines andchemokines correlated positively with the degree of accu-
mulation of α-syn in glial cells [26]. Together, these results
suggest that astroglial alpha-synuclein pathology is pro-
duced by direct transmission of neuronal alpha-synuclein
aggregates, causing inflammatory responses. This transmis-
sion step is thus an important mediator of pathogenic glial
responses and could qualify as a new therapeutic target.
Our data is also in line with previous studies showing
increased α-syn expression in Parkinson patient fibro-
blasts parallel to increased oxidative stress in these cells
[28]. Without an appropriate mechanism of uptake into
these distinct cell types, these observed patterns cannot
be fully evaluated. They do, however, suggest that α-syn
toxicity may not be restricted to the central and periph-
eral nervous system but may also be associated with
other systems such as the skin. For example, it might be
reasonable to hypothesise that α-syn aggregates can
Figure 6 Effects of α-syn on cell viability in human primary cortical neurons, astrocytes and skin-derived fibroblasts. Effect of
recombinant α-syn (5 μM) on extracellular LDH activity in (i) human primary cortical neurons, (ii) astrocytes and (iii) skin-derived fibroblasts
pre-treated with 5 μM recombinant α-syn for 24 hours. *p < 0.05 compared to non-treated cells (control); (n = 4 for each treatment group).
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other cells, and vice versa, hence leading to a reduction
in function which is not restricted to neuronal cells.
Mitochondrial dysfunction has been frequently docu-
mented in the neurodegenerative process that underlies
PD [10,28-35]. Despite this, the molecular events leading
to the observed dysfunction remains unclear. The goal
of this study was also to investigate the effects of recom-
binant α-syn cell viability and mitochondrial function inprimary human neurons, astrocytes and fibroblasts. Our
data shows a significant increase in lactate dehydrogen-
ase (LDH) release and indicating a reduction in cell via-
bility in α-syn treated cells compared to non-treated
controls. With regards to mitochondrial function, α-syn
exhibited a significant reduction in oxygen consumption
in these cells, as observed by an increase in the BCR ra-
tio and a decline in the UCR. Importantly, these data
also support a previous PD respiratory analysis study
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mitochondrial maximum respiration rate and increased
mitochondrial fragmentation [34].
While α-syn is a well known cytoplasmic protein, nu-
merous studies have shown that it has some affinity to
phospholipids, and vesicles [36,37]. Herein we have shown
that α-syn is also delivered to the mitochondria. Another
study has shown that α-syn is present in nanomolar
concentrations in neuronal culture medium [38]. Secreted
forms of α-syn have been shown to re-enter adjacent cells
leading to increased cytotoxicity via oxidative stress mech-
anisms [22,25]. In the present study, we showed that, in
cultured neurons, glial cells and skin-derived fibroblasts,
α-syn could form intracellular inclusions. Our study does
not rule out the possibility that the internalized recombin-
ant α-syn may be entangled with endogenous α-syn, and
that the α-syn expression visualised herein may consist of
both naturally occurring endogenous and recombinant ex-
ogenous α-syn. However, using our method, it is clear that
endogenous α-syn is only expressed at very low levels in
foetal tissue, and not detected using immunohistochemis-
try. Further work is warranted to investigate the binding
properties of α-syn in cultured human cells.
The current data is consistent with mitochondrial dys-
function as the converging pathway connecting a variety
of causes for PD. In fact, several causes of mitochondrial
dysfunction due to free radicals and lysosomal/prote-
asome dysfunction associated with α-syn have been
reported in PD [28,39,40]. One study showed a higher
frequency in somatic mitochondrial DNA deletion in the
substantia nigra of sporadic PD patients leading to defi-
ciency in the respiratory chain and increased generation
of reactive oxygen species [41]. These results are in line
with our current work indicating that PD may occur in
response to mitochondrial dysfunction, possibly due to
alterations in gene expression.
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